Supplemental
. Baseline characteristics and pre-admission medication of AHF patients who died compared to those who survived the first three months after onset of AHF All (N=132) Alive ( Data are presented as n (%) or as median and range (minimum to maximum). Differences between AHF patients who died and those who survived the first three months after onset of AHF were tested using Fisher's exact test or the Mann-Whitney U test; significant differences are depicted in bold.
Five patients had unknown status regarding 3-month survival.
AHF, acute heart failure; ACEI, angiotensinogen converting enzyme inhibitor; BMI, body mass index; EF, ejection fraction; JVD, jugular venous distension; MAP, mean arterial pressure; NYHA, New York Heart Association Functional Classification; SPAP, systolic pulmonary artery pressure. Urea ( Data are presented as median and range (minimum to maximum). Differences between AHF patients who died and those who survived the first three months after onset of AHF were tested with the Mann-Whitney U test; significant differences are depicted in bold.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; AHF, acute heart failure;
CRP, C-reactive protein; GFR, glomerular filtration rate; HDL-P, concentration of HDL particles; IL-6, interleukin-6; LDL, low-density lipoprotein; NT-proBNP, N-terminal pro brain natriuretic peptide. OR and CI are presented on the SD scale (increase per 1 SD); SDs for HDL3-C/SHDL-P, HDL2-C/LHDL-P, and THDL-C/THDL-P are 9.4, 31.5, and 21.8, respectively.
* The model was adjusted for age, sex, NT-proBNP, GFR, MAP, LDL-cholesterol, log(triglycerides), T2D, and CRP.
Significant results are depicted in bold.
CI, confidence interval; CRP, C-reactive protein; GFR, glomerular filtration rate; HDL-C, highdensity lipoprotein cholesterol; LDL, low-density lipoprotein; LHDL-P, concentrations of large HDL particles; MAP, mean arterial pressure; NT-proBNP, N-terminal pro brain natriuretic peptide; OR, odds ratio; SD, standard deviation; SHDL-P, concentration of small HDL particles; T2D, type 2 diabetes.
